Azacitidine vs a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 3 Trial of Azacitidine Versus a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated Acute Myeloid Leukemia
Cancer 2021 Feb 24;[EPub Ahead of Print], S Vives, D Martínez-Cuadrón, J Bergua Burgues, L Algarra, M Tormo, MP Martínez-Sánchez, J Serrano, P Herrera, F Ramos, O Salamero, E Lavilla, JL López-Lorenzo, C Gil, B Vidriales, JF Falantes, A Serrano, J Labrador, MJ Sayas, MÁ Foncillas, ML Amador Barciela, MT Olave, M Colorado, A Gascón, MÁ Fernández, A Simiele, MM Pérez-Encinas, R Rodríguez-Veiga, O García, J Martínez-López, E Barragán, B Paiva, MÁ Sanz, P MontesinosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.